Cargando...

Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders

Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the liter...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karbasi-Afshar, R, Taheri, S
Formato: Artigo
Lenguaje:Inglês
Publicado: Shahid Sadoughi University of Medical Sciences 2013
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3921880/
https://ncbi.nlm.nih.gov/pubmed/24575284
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!